Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jf Hans Piepenbrink"'
Autor:
Ruaraidh Hill, Christian Hierländer, Carolina Zampirolli Dias, Tomasz Bochenek, Ott Laius, Lars L. Gustafsson, Tracey-Lea Laba, Arianit Jakupi, Øyvind Melien, Wija Oortwijn, Luka Voncina, Durhane Wong-Rieger, Caridad Pontes, Jf Hans Piepenbrink, Magdalene Wladysiuk, Guenka Petrova, Patricia Vella Bonanno, Corinne Zara, Robert Sauermann, Steven Simoens, Olayinka O Ogunleye, Amanj Kurdi, Wouter Hamelinck, Wania Cristina Silva, Dzintars Gotham, Seung Jin Bae, Johanna C Meyer, Roberta Joppi, Janet Wale, Admir Malaj, John Yfantopoulos, Gisbert Selke, Angela Timoney, Brian Godman, Vincent de Valk, Andrew Hill, Merce Obach Cortadellas, D Tomek, Hye-Young Kwon, Irene Langner, Jurij Fürst, Iva Selke Krulichová, Antony P. Martin, Jolanta Gulbinovič, Iris Hoxha, Eleonora Allocati, Stuart McTaggart, Ieva Greiciute-Kuprijanov, Vanda Marković-Peković, Ileana Mardare
Publikováno v:
Expert review of pharmacoeconomics and outcomes research, Abingdon : Taylor and Francis Ltd., 2021, vol. 21, iss. 4, p. 527-540
Expert Review of Pharmacoeconomics and Outcomes Research, 21, 527-540
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
Expert Review of Pharmacoeconomics and Outcomes Research, 21, 4, pp. 527-540
Expert review of pharmacoeconomics & outcomes research
Expert Review of Pharmacoeconomics and Outcomes Research, 21, 527-540
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
Expert Review of Pharmacoeconomics and Outcomes Research, 21, 4, pp. 527-540
Expert review of pharmacoeconomics & outcomes research
Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dfe77330e4296c7333cde6b78e19b86
https://repository.vu.lt/VU:ELABAPDB88291411&prefLang=en_US
https://repository.vu.lt/VU:ELABAPDB88291411&prefLang=en_US
Autor:
Stuart McTaggart, Irene Langer, Ieva Greiciute-Kuprijanov, Patricia Vella Bonanno, Anne Marthe Ringerud, Angela Timoney, Jurij Fürst, John Yfantopoulos, Arianit Jakupi, Tatjana Ponorac, Robert Sauermann, Vanda Marković-Peković, Dzintars Gotham, D Tomek, Admir Malaj, Corinne Zara, Christian Hierländer, Peter Skiold, Vincent de Valk, Guenka Petrova, Antony P. Martin, JF (Hans) Piepenbrink, Jolanta Gulbinovič, Janet Wale, Iris Hoxha, Wouter Hamelinck, Maria Juhasz-Haverinen, Nataša Grubiša, Steven Simoens, Catherine Sermet, Ott Laius, Gisbert Selke, Robert Plisko, Celia C. Rothe, Tomasz Bochenek, Andrew F. Hill, Tanja Novakovic, Zornitza Mitkova, Ileana Mardare, Alan Haycox, Roberta Joppi, Carolin Hagen, Magdalene Wladysiuk, Amanj Kurdi, Elita Poplavska, Brian Godman, Merce Obach Cortadellas, Mark Parker
Publikováno v:
Generics and Biosimilars Initiative Journal
Introduction: There are appreciable concerns among European health authorities with growing expenditure on cancer medicines and issues of sustainability. The enhanced use of low cost generics could help. Aims: Consequently, there is a need to compreh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0009ea13d1e0e5433c3f43ffb8a0034b
https://ruj.uj.edu.pl/xmlui/handle/item/257394
https://ruj.uj.edu.pl/xmlui/handle/item/257394